Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of UX007 (triheptanoin) in Glut1 Deficiency Syndrome
2015-000389-69Phase 2Terminated
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triheptanoin in Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Long-term safety of UX007 (triheptanoin). Started Jul 2016; status: terminated.
02
Drugs
triheptanoin
03
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS)
Beyond the preview
Go deeper on 2015-000389-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000389-69.